Multimorbid pathology at psoriasis (scientific review)

Abstract

Chronic auto-inflammatory process in psoriasis is associated with the involvement of internal organs and systems, as well as the development of several systemic disorders: heart failure, psoriatic arthritis, diabetes, obesity, etc. In this regard, the purpose of our study is to integrate information about comorbid and concomitant pathology in patients with psoriasis. Data on the biological aspects of the increased risk of occurrence and adverse cardiovascular outcome of myocardial infarction, stroke and cardiovascular mortality in patients with psoriasis are supported by clinical observations on the relationship of the course of coronary heart disease with the area of skin lesion. The association between the presence of obesity and an increased level of proinflammatory cytokines has been confirmed, which may be one of the triggers for the development of psoriatic arthritis associated with early disability of patients with psoriasis. There was a greater incidence of non-response to psoriasis treatment among obese patients. Cardiovascular complications are the most common cause of death for patients with psoriasis. Identifying common combinations of comorbid and concomitant diseases in the main chronic disease can serve as a basis for the development of tactics and criteria for patient management in order to optimize treatment.

Keywords

psoriasis / comorbid and concomitant diseases / psoriatic arthritis / cardiovascular pathology

References

[1] Kungurov NV, Filimonkova NN, Tuzankina IA. Psoriasis Vulgaris. Ekaterinburg: Izd-vo Ural’skogo un-ta; 2002. 200 p. (In Russ.)

[2] Кунгуров Н.В., Филимонкова Н.Н., Тузанкина И.А. Псориатическая болезнь. Екатеринбург: Изд-во Уральского ун-та, 2002. 200 с.

[3] Sorokina EV, Bisheva IV. The role of cells of the innate immune system in psoriasis. Vestnik dermatologii i venerologii. 2022;98(5):59–64. EDN: OKYHPG doi: 10.25208/vdv1330

[4] Сорокина Е.В., Бишева И.В. Роль клеток врожденной иммунной системы при псориазе // Вестник дерматологии и венерологии. 2022. Т. 98, № 5. С. 59–64. EDN: OKYHPG doi: 10.25208/vdv1330

[5] Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi: 10.1111/j.1600-0625.2011.01261.x

[6] Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity // Exp Dermatol. 2011. Vol. 20, N. 4. P. 303–307. doi: 10.1111/j.1600-0625.2011.01261.x

[7] Mazurov VI, Trofimov EA, Gaidukova IZ. The place of a phosphodiesterase 4 inhibitor in the treatment strategy for psoriatic arthritis. Modern Rheumatology Journal. 2018;12(1):41–46. EDN: XPUTRR doi: 10.14412/1996-7012-2018-1-41-46

[8] Мазуров В.И., Трофимов Е.А., Гайдукова И.З. Место ингибитора фосфодиэстеразы 4-го типа в стратегии лечения псориатического артрита // Современная ревматология. 2018. Т. 12, № 1. С. 41–46. EDN: XPUTRR doi: 10.14412/1996-7012-2018-1-41-46

[9] Potekaev NN, Zhukova OV, Artem’eva SI. Psoriasis: a personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. Medical Council. 2020;12:28–34. EDN: MCMQOZ doi: 10.21518/2079-701X-2020-12-28-34

[10] Потекаев Н.Н., Жукова О.В., Артемьева С.И. Псориаз: персонифицированный подход к терапии. Предпочтительный выбор системных агентов с учетом коморбидных патологий // Медицинский совет. 2020. Т. 12. С. 28–34. EDN: MCMQOZ doi: 10.21518/2079-701X-2020-12-28-34

[11] Olisova OYu, Garanyan LG. Comorbidities in psoriasis Russian Journal of Skin and Venereal Diseases. 2016;19(6):346–348. EDN: XUWDTR doi: 10.18821/1560-9588-2016-19-6-346-348

[12] Олисова О.Ю., Гаранян Л.Г. Коморбидности при псориазе // Российский журнал кожных и венерических болезней. 2016. Т. 19, № 6. С. 346–348. EDN: XUWDTR doi: 10.18821/1560-9588-2016-19-6-346-348

[13] Alikbaev TZ, Frolova EV, Gulordava MD, et al. Modern ideas about the pathogenesis, clinic and treatment of severe psoriasis. Problems in Medical Mycology. 2021;23(4):9–16. EDN: STXXRQ doi: 10.24412/1999-6780-2021-4-9-16

[14] Аликбаев Т.З., Фролова Е.В., Гулордава М.Д., и др. Современные представления о патогенезе, клинике и течении тяжелого псориаза // Проблемы медицинской микологии. 2021. Т. 23, № 4. С. 9–16. EDN: STXXRQ doi: 10.24412/1999-6780-2021-4-9-16

[15] Patrick MT, Li Q, Wasikowski R, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13(1):6565. doi: 10.1038/s41467-022-34323-4

[16] Patrick M.T., Li Q., Wasikowski R., et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease // Nat Commun. 2022. Vol. 13, N. 1. P. 6565. doi: 10.1038/s41467-022-34323-4

[17] Reed WB, Becker SW, Rohde R, Heiskell CL. Psoriasis and arthritis. Clinicopathologic study. Arch Dermatol. 1961;83:541–548. doi: 10.1001/archderm.1961.01580100005001

[18] Reed W.B., Becker S.W., Rohde R., Heiskell C.L. Psoriasis and arthritis. Clinic opathologic study // Arch Dermatol. 1961. Vol. 83. P. 541–548. doi: 10.1001/archderm.1961.01580100005001

[19] Mehta NN, Krishnamoorthy P, Yu Y, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–798. doi: 10.1016/j.jaad.2012.05.016

[20] Mehta N.N., Krishnamoorthy P., Yu.Y., et al. The impact of psoriasis on 10-year Framingham risk // J Am Acad Dermatol. 2012. Vol. 67, N. 4 P. 796–798. doi: 10.1016/j.jaad.2012.05.016

[21] Smirnova IO, Vladimirova IS. Psoriasis and cardiovascular comorbidity (literature review). Medical alphabet. 2020;(6):18–21. EDN: QFFIMW doi: 10.33667/2078-5631-2020-6-18-21

[22] Смирнова И.О., Владимирова И.С. Псориаз и сердечно-сосудистая коморбидность (обзор литературы) // Медицинский алфавит. 2020. № 6. С. 18–21. EDN: QFFIMW doi: 10.33667/2078-5631-2020-6-18-21

[23] Armstrong AW, Guérin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968–977. doi: 10.1016/j.jaad.2015.02.1095

[24] Armstrong A.W., Guérin A., Sundaram M., et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications // J Am Acad Dermatol. 2015. Vol. 72, N. 6. P. 968–977. doi: 10.1016/j.jaad.2015.02.1095

[25] Sofidis G, Stalikas N, Papathemeli D, et al. Correlation of psoriasis severity with angiographic coronary artery disease complexity: a cross-sectional study. J Eur Acad Dermatol Venereol. 2021;35(6):372–373. doi: 10.1111/jdv.17143

[26] Sofidis G., Stalikas N., Papathemeli D., et al. Correlation of psoriasis severity with angiographic coronary artery disease complexity: a cross-sectional study // J Eur Acad Dermatol Venereol. 2021. Vol. 35, N. 6. P. 372–373. doi: 10.1111/jdv.17143

[27] Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017;136(3):263–276. doi: 10.1161/CIRCULATIONAHA.116.026859

[28] Lerman J.B., Joshi A.A., Chaturvedi A., et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study // Circulation. 2017. Vol. 136, N. 3. P. 263–276. doi: 10.1161/CIRCULATIONAHA.116.026859

[29] Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579

[30] Boehncke W.-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences // Front Immunol. 2018. Vol. 9. P. 579. doi: 10.3389/fimmu.2018.00579

[31] Mansouri B, Kivelevitch D, Natarajan B, et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes. JAMA Dermatol. 2016;152(11):1244–1253. doi: 10.1001/jamadermatol.2016.2907

[32] Mansouri B., Kivelevitch D., Natarajan B., et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes // JAMA Dermatol. 2016. Vol. 152, N. 11. P. 1244–1253. doi: 10.1001/jamadermatol.2016.2907

[33] Gupta Y, Möller S, Zillikens D, et al. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Exp Dermatol. 2013;22(8):552–553. doi: 10.1111/exd.12192

[34] Gupta Y., Möller S., Zillikens D., et al. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease // Exp Dermatol. 2013. Vol. 22, N. 8. P. 552–553. doi: 10.1111/exd.12192

[35] Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi: 10.1001/jama.296.14.1735

[36] Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis // JAMA. 2006. Vol. 296, N. 14. P. 1735–1741. doi: 10.1001/jama.296.14.1735

[37] Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76. doi: 10.1016/j.jaad.2021.06.883

[38] Enos C.W., Ramos V.L., McLean R.R., et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry // J Am Acad Dermatol. 2022. Vol. 86, N. 1. P. 68–76. doi: 10.1016/j.jaad.2021.06.883

[39] Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–592. doi: 10.1111/j.1365-2133.2010.09941.x

[40] Abuabara K., Azfar R.S., Shin D.B., et al. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K. // Br J Dermatol. 2010. Vol. 163. P. 586–592. doi: 10.1111/j.1365-2133.2010.09941.x

[41] Goto H, Nakatani E, Yagi H, et al. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021;2:51–61. doi: 10.1016/j.jdin.2020.10.011

[42] Goto H., Nakatani E., Yagi H., et al. Late-onset development of psoriasis in Japan: a population-based cohort study // JAAD Int. 2021. Vol. 2. P. 51–61. doi: 10.1016/j.jdin.2020.10.011

[43] Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273–1277. doi: 10.1136/annrheumdis-2012-201299

[44] Love T.J., Zhu Y., Zhang Y., et al. Obesity and the risk of psoriatic arthritis: a population-based study // Ann Rheum Dis. 2012. Vol. 71, N. 8. P. 1273–1277. doi: 10.1136/annrheumdis-2012-201299

[45] Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019;21(1):17. doi: 10.1186/s13075-019-1810-5

[46] Klingberg E., Bilberg A., Björkman S., et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study // Arthritis Res Ther. 2019. Vol. 21, N. 1. P. 17. doi: 10.1186/s13075-019-1810-5

[47] Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013;52(1):62–67. doi: 10.1093/rheumatology/kes242

[48] Russolillo A., Iervolino S., Peluso R., et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management // Rheumatology (Oxford). 2013. Vol. 52, N. 1. P. 62–67. doi: 10.1093/rheumatology/kes242

[49] Moroni L, Farina N, Dagna L. Obesity and its role in the management of rheumatoid and psoriatic arthritis. Clin Rheumatol. 2020;39(4):1039–1047. doi: 10.1007/s10067-020-04963-2

[50] Moroni L., Farina N., Dagna L. Obesity and its role in the management of rheumatoid and psoriatic arthritis // Clin Rheumatol. 2020. Vol. 39, N. 4. P. 1039–1047. doi: 10.1007/s10067-020-04963-2

[51] Llamas-Velasco M, Ovejero-Merino E, Salgado-Boquete L. Obesity — a risk factor for psoriasis and COVID-19. Actas Dermosifiliogr. 2020;112(6):489–494. (In Spanish) doi: 10.1016/j.ad.2020.12.001

[52] Llamas-Velasco M., Ovejero-Merino E., Salgado-Boquete L. Obesity — a risk factor for psoriasis and COVID-19 // Actas Dermosifiliogr. 2020. Vol. 112, N. 6. P. 489–494. (In Spanish) doi: 10.1016/j.ad.2020.12.001

[53] Karmacharya P, Ogdie A, Eder L. Psoriatic arthritis and the association with cardiometabolic disease: A narrative review. Ther Adv Musculoskelet Dis. 2021;13:1759720X21998279. doi: 10.1177/1759720X21998279

[54] Karmacharya P., Ogdie A., Eder L. Psoriatic arthritis and the association with cardiometabolic disease: A narrative review // Ther Adv Musculoskelet Dis. 2021. Vol. 13. P. 1759720X21998279. doi: 10.1177/1759720X21998279

[55] Castaldo G, Rastrelli L, Galdo G, et al. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition. 2020;74:110757. doi: 10.1016/j.nut.2020.110757

[56] Castaldo G., Rastrelli L., Galdo G., et al. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial // Nutrition. 2020. Vol. 74. P. 110757. doi: 10.1016/j.nut.2020.110757

[57] Nasonov EL, Korotaeva TV, Lila AM, Kubanov AA. Can the development of psoriatic arthritis be prevented in patients with psoriasis? Rheumatology Science and Practice. 2019;57(3):250–254. EDN: BWOEZJ doi: 10.14412/1995-4484-2019-250-254

[58] Насонов Е.Л., Коротаева Т.В., Лила А.М., Кубанов А.А. Можно ли предотвратить развитие псориатического артрита у пациентов с псориазом? // Научно-практическая ревматология. 2019. Т. 57, № 3. С. 250–254. EDN: BWOEZJ doi: 10.14412/1995-4484-2019-250-254

[59] Ceccarelli M, Venanzi Rullo E, Berretta M, et al. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection. Dermatol Ther. 2021;34(1):e14660. doi: 10.1111/dth.14660

[60] Ceccarelli M., Venanzi Rullo E., Berretta M., et al. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection // Dermatol Ther. 2021. Vol. 34, N. 1. P. e14660. doi: 10.1111/dth.14660

[61] Lila AM, Nasonov EL, Korotaeva TV. Psoriatic arthritis: pathogenetic features and innovative therapies. Rheumatology Science and Practice. 2018;56(6):685–691. EDN: MSVMHQ doi: 10.14412/1995-4484-2018-685-691

[62] Лила А.М., Насонов Е.Л., Коротаева Т.В. Псориатический артрит: патогенетические особенности и инновационные методы терапии // Научно-практическая ревматология. 2018. Т. 56, № 6. С. 685–691. EDN: MSVMHQ doi: 10.14412/1995-4484-2018-685-691

[63] Mody E, Husni ME, Schur P, Qureshi AA. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol. 2007;157(5):1050–1051. doi: 10.1111/j.1365-2133.2007.08139.x

[64] Mody E., Husni M.E., Schur P., Qureshi A.A. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience // Br J Dermatol. 2007. Vol. 157, N. 5. P. 1050–1051. doi: 10.1111/j.1365-2133.2007.08139.x

[65] Rozumbaeva LP, Kozlova IV, Bykova AP. Comorbidity of diseases of the liver, biliary tract and psoriasis. Experimental and Clinical Gastroenterology. 2015;114(2):24–28. EDN: THKCKL

[66] Розумбаева Л.П., Козлова И.В., Быкова А.П. Коморбидность заболеваний печени, билиарного тракта и псориаза // Экспериментальная и клиническая гастроэнтерология. 2015. T. 114, № 2. С. 24–28. EDN: THKCKL

[67] Bakulev AL. Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients. Vestnik dermatologii i venerologii. 2017;93(1):38–45. EDN: YGRYAN doi: 10.25208/0042-4609-2017-93-1-38-45

[68] Бакулев А.Л. Метотрексат: к вопросу об эффективности и безопасности применения препарата у больных псориазом // Вестник дерматологии и венерологии. 2017. Т. 93, № 1. С. 38–45. EDN: YGRYAN doi: 10.25208/0042-4609-2017-93-1-38-45

[69] Zhukov AS, Khotko AA, Khairutdinov VR, Samtsov AV. Profiles of patients with psoriasis for appointment gene-engineering biological therapy – clinical justification. Vestnik dermatologii i venerologii. 2020;96(1):58–66. EDN: YMOWXW doi: 10.25208/vdv550-2020-96-1-58-66

[70] Жуков А.С., Хотко А.А., Хайрутдинов В.Р., Самцов А.В. Профили больных псориазом для назначения генно-инженерной биологической терапии — клиническое обоснование // Вестник дерматологии и венерологии. 2020. Т. 96, № 1. С. 58–66. EDN: YMOWXW doi: 10.25208/vdv550-2020-96-1-58-66

[71] Abdulganieva DI, Bakulev AL, Belousova EA, et al. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn’s disease). Modern Rheumatology Journal. 2018;12(3):4–18. EDN: YOCLQT doi: 10.14412/1996-7012-2018-3-4-18

[72] Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А., и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона) // Современная ревматология. 2018. Т. 12, № 3. С. 4–18. EDN: YOCLQT doi: 10.14412/1996-7012-2018-3-4-18

[73] Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. doi: 10.1016/j.jaad.2008.02.039

[74] Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics // J Am Acad Dermatol. 2008. Vol. 58, N. 5. P. 826–850. doi: 10.1016/j.jaad.2008.02.039

[75] Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi: 10.1111/bjd.18245

[76] Korman N.J. Management of psoriasis as a systemic disease: what is the evidence? // Br J Dermatol. 2020. Vol. 182, N. 4. P. 840–848. doi: 10.1111/bjd.18245

RIGHTS & PERMISSIONS

Eco-Vector